Home Wellness Insights

29Jul

PCOS and GLP-1 Statistics 2026 | Prescribing Trends & Clinical Data

PCOS and GLP-1 Statistics 2026: Off-Label Prescribing Data & Clinical Trial Results | GoalBMI Wellness

📊 Statistics Report — Updated July 2026

Why Prescribing for This Condition Jumped Seven-Fold in Four Years

Polycystic ovary syndrome affects up to 13% of reproductive-age women, and GLP-1 prescribing among this population has risen seven-fold since 2021. Here’s what the clinical trial data actually shows about weight loss, menstrual regularity, and where the evidence is strongest.

📅 Last Updated: July 2026 ⏱ 12 min read ✔ Physician Reviewed 📚 9 Cited Sources

6-13%

Of reproductive-age women affected by PCOS

Truveta / Telehealth Ally, 2026

17.6%

Of PCOS patients prescribed semaglutide or tirzepatide in 2025

Truveta, May 2026

Increase in GLP-1 prescribing among PCOS patients since 2021

Truveta, 2026

60-75%

Of treated patients saw restored ovulation in larger trials

WeightSherpa, 2026

Polycystic ovary syndrome is the most common endocrine disorder in reproductive-age women, and it’s increasingly understood as a metabolic condition rooted in insulin resistance — not simply a reproductive one. That reframing has driven a dramatic rise in GLP-1 prescribing for PCOS patients, almost entirely off-label. This page compiles the current prescribing data and what the clinical trials actually show.

Section 01

How Common Is PCOS, and Why Does It Matter Here?

PCOS prevalence estimates vary by diagnostic criteria used, but every major estimate places it as the most common hormonal disorder in women of reproductive age.

6-13%

Of reproductive-age women affected, depending on diagnostic criteria

~70%

Of women with PCOS have underlying insulin resistance

Most prevalent endocrinopathy in women of reproductive age

A paradigm shift in how PCOS is understood: The 2025 Lancet Diabetes & Endocrinology Commission explicitly reframed PCOS as “a complication of obesity” rather than a standalone reproductive condition. The reasoning: hormonal dysfunction in adipose tissue and hyperinsulinemia from insulin resistance can act similarly to reproductive hormones, directly contributing to the hyperandrogenism that defines PCOS. This reframing is a major driver of why GLP-1 medications — designed to address insulin resistance — have moved into PCOS care. (Source: Expert Review of Endocrinology & Metabolism, 2025)

Section 02

Prescribing Has Risen Seven-Fold Since 2021

Real-world prescribing data tracks a clear, accelerating trend as evidence has accumulated.

Semaglutide/Tirzepatide Prescribing Among PCOS Patients, 2021–2025 (%)

Source: Truveta real-world data analysis, May 2026.

📈

From 2.4% to 17.6% in Four Years

A Truveta analysis of real-world data from January 2021 to September 2025 found that semaglutide or tirzepatide prescribing among women with PCOS rose from 2.4% in 2021 to 17.6% in 2025 — more than a seven-fold increase. The analysis compared two patient cohorts: those prescribed semaglutide or tirzepatide, and those with a recorded PCOS diagnosis. (Source: Truveta, May 2026)

Important limitation from the researchers themselves: This analysis covered only semaglutide and tirzepatide, and did not account for other common PCOS treatments such as metformin, combined oral contraceptives, or anti-androgen therapies. The findings show a prescribing trend, not a complete picture of PCOS treatment overall or a head-to-head comparison with standard therapies. (Source: Truveta, 2026)

Section 03

On-Label vs. Off-Label: A Critical Distinction

No GLP-1 medication is FDA-approved specifically for PCOS. Whether a prescription is on-label or off-label depends entirely on the patient’s individual weight criteria.

Medication	FDA-Approved Indication	Status for PCOS
Semaglutide (Wegovy®)	Chronic weight management, BMI ≥30, or ≥27 with a comorbidity	On-label if weight criteria met
Tirzepatide (Zepbound®)	Chronic weight management, same criteria as Wegovy®	On-label if weight criteria met
Tirzepatide (Mounjaro®)	Type 2 diabetes management	On-label only if diabetic
Any GLP-1 for PCOS symptoms specifically	No PCOS-specific approval exists	Off-label

⚖️

Off-Label Prescribing Is Legal and Common in Medicine

For a woman with PCOS who also has obesity or overweight with a metabolic comorbidity, Wegovy® or Zepbound® can be prescribed on-label for the weight management indication — the PCOS context doesn’t change the prescribing legality. For lean women with PCOS who don’t meet weight eligibility criteria, prescribing a GLP-1 specifically for PCOS symptoms is fully off-label. Off-label prescribing is legal, widespread across medicine, and clinically appropriate when supported by evidence — which reproductive endocrinologists increasingly consider to be the case here. (Source: Telehealth Ally, April 2026)

Section 04

What the Clinical Trials Actually Show

The evidence base is strongest for semaglutide, with tirzepatide data still accumulating.

10-15%

Weight loss with semaglutide 1.0–2.4mg over 6-12 months

60-75%

Restoration of ovulation in larger semaglutide trials

18.81%

Mean weight loss with tirzepatide at 10 months, real-world data

🔬

Semaglutide Is the Better-Evidenced Agent

Several randomized trials conducted between 2021 and 2025 showed semaglutide 1.0–2.4mg weekly produces roughly 10–15% weight loss in PCOS patients over 6–12 months, with parallel improvements in menstrual cycle frequency, testosterone, sex hormone-binding globulin (SHBG), and HOMA-IR (a marker of insulin resistance). As of April 2026, no PCOS-dedicated randomized controlled trial has published for tirzepatide — the evidence base for tirzepatide in PCOS remains real-world and observational rather than trial-based. (Source: WeightSherpa, March 2026)

📊

ObesityWeek 2025 Real-World Tirzepatide Data

Real-world data presented at ObesityWeek 2025 showed over 90% of PCOS patients lost at least 10% of body weight within 10 months on tirzepatide, with a mean weight loss of 18.81% — comparable to tirzepatide’s general SURMOUNT-1 trial results (22.5% at the highest dose). This is observational, real-world clinic data rather than a randomized controlled trial. (Source: iPharma Pharmacy, 2026)

A 2026 systematic review and meta-analysis (Prospero CRD42024535096) searched Cochrane Library, EMBASE, and Medline through September 2024, identifying 9,654 studies and including 11 randomized controlled trials comparing GLP-1 receptor agonists against no treatment, placebo, lifestyle intervention, oral contraceptives, anti-androgens, or metformin in PCOS patients. GLP-1 RAs as an add-on showed a reduction in BMI compared to controls (mean difference −1.38 kg/m², low certainty evidence). Evidence for lipid outcomes was insufficient to draw firm conclusions. (Source: PubMed / systematic review, March 2026)

Section 05

Why GLP-1s Address the Root Cause, Not Just Symptoms

The clinical rationale for using GLP-1 medications in PCOS rests on treating the underlying metabolic driver rather than individual symptoms.

Up to 70% of women with PCOS have insulin resistance, which drives excess androgen production, irregular menstrual cycles, and treatment-resistant weight gain. This reframes GLP-1 therapy as a metabolic intervention with reproductive benefits, rather than simply a weight-loss shortcut — addressing why the weight was difficult to lose in the first place. (Source: iPharma Pharmacy, 2026)

Tirzepatide’s Dual Mechanism May Offer a Compliance Advantage

Because tirzepatide activates both GLP-1 and GIP receptors, researchers have hypothesized its dual mechanism may reduce the intensity of gastrointestinal side effects compared to single-receptor GLP-1 agonists — a meaningful consideration since GI side effects are a leading cause of treatment discontinuation. However, tirzepatide “may not benefit those who are of normal weight,” and its use is specifically considered valuable for PCOS patients who are obese with metabolic syndrome. (Source: Journal of Clinical Medicine, 2023)

👩‍⚕️

Slower Titration May Help PCOS Patients Specifically

Some clinical sources note that women with PCOS “often tolerate medication differently” and may benefit from slower, more personalized dose titration to ease gastrointestinal side effects that otherwise lead many patients to discontinue treatment too early. This underscores the value of individualized, physician-supervised dosing rather than a fixed one-size-fits-all schedule.

Section 06

Important Considerations for PCOS Patients Specifically

Two considerations apply specifically to reproductive-age women with PCOS that don’t necessarily apply to the general GLP-1 patient population.

Pregnancy is a contraindication. Because GLP-1 medications can improve fertility by restoring ovulation, patients trying to conceive need specific guidance: GLP-1 medications should be stopped at least two months before attempting to conceive. Animal studies have associated early fetal exposure to incretin-based drugs with fetal growth restriction and embryotoxicity. Data from pregnancies occurring during clinical development, hospital-based databases, and the European Medicines Agency’s semaglutide pregnancy registry have not shown an increased rate of major congenital anomalies — but all analyses to date were severely underpowered due to small sample sizes. (Sources: WeightSherpa, 2026; Expert Review of Endocrinology & Metabolism, 2025)

🤰

The Fertility Paradox Worth Discussing With Your Provider

For patients not actively trying to conceive, restored ovulation can be an unexpected and clinically significant side effect of treatment — meaning contraception planning should be part of the conversation when starting GLP-1 therapy for PCOS, not an afterthought.

Program Access

GLP-1 Support for PCOS at GoalBMI Wellness

GoalBMI Wellness provides physician-supervised GLP-1 programs for eligible patients, with individualized dose titration and evaluation for weight-related eligibility criteria — including patients whose PCOS is accompanied by obesity or overweight with a metabolic comorbidity.

GoalBMI Wellness GLP-1 program pricing with insurance and self-pay options

Book a Consultation Explore Medical Weight Loss Programs

Real Patient Outcomes

Before & After — Physician-Supervised Results at GoalBMI Wellness

Individualized titration and consistent monitoring matter especially for patients managing PCOS alongside weight goals. These results reflect physician-supervised GLP-1 programs at GoalBMI Wellness.

Before and after semaglutide and tirzepatide weight loss results — GoalBMI Wellness physician-supervised patients

See more patient before & after results →

Results disclaimer: Individual results may vary. Photos represent real patients from physician-supervised GoalBMI Wellness programs shared with patient consent. Results depend on individual health factors, program adherence, and clinical evaluation.

Section 07

How the Evidence Base Developed

2017–2020

Early Liraglutide Studies

Smaller, older studies including a LEAD-Metabolism PCOS sub-group show 5–8% weight loss and significant improvement in menstrual regularity with liraglutide, an earlier-generation GLP-1.

2021

GLP-1 Prescribing for PCOS Begins at Low Levels

Semaglutide/tirzepatide prescribing among PCOS patients sits at just 2.4%, per later Truveta analysis — an emerging but uncommon practice.

2021–2025

Semaglutide RCTs Accumulate

Several randomized trials establish semaglutide 1.0–2.4mg weekly produces 10–15% weight loss in PCOS patients, with parallel improvements in ovulation, testosterone, SHBG, and insulin resistance markers.

2023

Tirzepatide’s Theoretical Rationale Published

A Journal of Clinical Medicine review outlines tirzepatide’s potential utility for PCOS via its dual GLP-1/GIP mechanism, while noting formal PCOS-specific trial data remains absent.

September 2024

Systematic Review Search Cutoff

A comprehensive systematic review and meta-analysis searches major databases, ultimately including 11 RCTs comparing GLP-1 RAs against standard PCOS treatments and controls.

2025

Lancet Commission Reframes PCOS as an Obesity Complication

The Lancet Diabetes & Endocrinology Commission explicitly names PCOS as a complication of obesity — a significant clinical reframing that accelerates the case for GLP-1 therapy in this population.

ObesityWeek 2025

Real-World Tirzepatide Data Presented

Real-world clinic data shows over 90% of PCOS patients achieving at least 10% weight loss within 10 months on tirzepatide, with 18.81% mean weight loss — though still without a dedicated randomized controlled trial.

2026

Prescribing Reaches 17.6%

Truveta real-world data confirms GLP-1 prescribing among PCOS patients has risen more than seven-fold since 2021, reaching 17.6% by 2025 — now considered by many reproductive endocrinologists a reasonable option after metformin.

Section 08

Frequently Asked Questions

No. No GLP-1 medication carries an FDA-approved indication specifically for polycystic ovary syndrome. Semaglutide (Wegovy®) and tirzepatide (Zepbound®) are approved for chronic weight management, and Mounjaro® is approved for type 2 diabetes. For PCOS patients who also meet weight-related eligibility criteria, prescribing is on-label under the weight management indication. For lean PCOS patients or when prescribed specifically for PCOS symptoms, use is off-label — which is legal and common in medicine when supported by evidence.

Real-world data from Truveta shows semaglutide or tirzepatide prescribing among women with PCOS rose from 2.4% in 2021 to 17.6% in 2025 — more than a seven-fold increase over four years. This reflects growing clinical acceptance as evidence accumulated, though the analysis covered only these two specific medications and not the full range of PCOS treatments.

Evidence suggests yes for many patients. Larger semaglutide trials showed restoration of ovulation in 60–75% of treated patients, alongside improvements in testosterone, SHBG, and insulin resistance markers. Because of this fertility effect, patients not trying to conceive should discuss contraception planning with their provider, and those who are trying to conceive should discuss the recommended two-month washout period before attempting pregnancy.

Semaglutide has the stronger clinical trial evidence base for PCOS specifically, with several randomized controlled trials published between 2021 and 2025. As of April 2026, no dedicated randomized controlled trial for tirzepatide in PCOS has published — its evidence comes from real-world clinic data, which shows comparable or greater weight loss (18.81% mean at 10 months) but hasn’t been validated in a PCOS-specific RCT. Your provider can help weigh these tradeoffs for your individual situation.

No — GLP-1 medications should be stopped at least two months before attempting to conceive, as pregnancy is a contraindication. Animal studies have linked early fetal exposure to fetal growth restriction and embryotoxicity, though human pregnancy registry data so far has not shown an increased rate of major congenital anomalies. This data remains limited due to small sample sizes, so caution and provider guidance are essential if you are planning a pregnancy.

References

Sources & References

1Truveta (May 13, 2026). Rising Use of GLP-1 Medications Among Women with PCOS. truveta.com
2Expert Review of Endocrinology & Metabolism (2025). Reframing Polycystic Ovary Syndrome as a Complication of Obesity: The Evolving Role of Incretin-Based Therapies. tandfonline.com
3WeightSherpa (March 28, 2026). GLP-1s for PCOS: What the Evidence Actually Shows in 2026. weightsherpa.com
4Anala A.D. et al. (2023). The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome. Journal of Clinical Medicine 12(14), 4575. pmc.ncbi.nlm.nih.gov
5iPharma Pharmacy (2026). Semaglutide & Tirzepatide for PCOS: Treating the Root Cause. ipharmapharmacy.com
6PubMed (March 4, 2026). GLP-1 Receptor Agonist Treatment in Women with Polycystic Ovary Syndrome — A Systematic Review and Meta-Analysis. pubmed.ncbi.nlm.nih.gov
7Telehealth Ally (April 28, 2026). PCOS and GLP-1 Medications: A Complete Evidence Review. telehealthally.com
8Jastreboff A.M. et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 387(3), 205–216. doi.org/10.1056/NEJMoa2206038
9Wilding J.P.H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM 384(11), 989–1002. doi.org/10.1056/NEJMoa2032183

Medically Reviewed by Karla K. Mioduchoski, FNP-BC

Board-Certified Family Nurse Practitioner — GoalBMI Wellness

Karla K. Mioduchoski, FNP-BC is a board-certified Family Nurse Practitioner providing physician-supervised medical weight loss, GLP-1 support, and telehealth wellness care through GoalBMI Wellness. All clinical trial and prescribing data in this article was reviewed for accuracy in July 2026.

Medical Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. No GLP-1 medication is FDA-approved specifically for PCOS; use for this purpose may be on-label (if weight criteria are met) or off-label, and is determined individually by a licensed provider. GLP-1 medications are contraindicated in pregnancy and should be discontinued at least two months before attempting to conceive — discuss family planning with your provider before starting treatment. Individual results and eligibility vary. In a medical emergency, call 911.

Get Started

Book an appointment and take the first step toward better health.

Book Now